Results 91 to 100 of about 22,676 (187)

HASH(0x563d44119a08) [PDF]

, 2009
HASH(0x563d44067a70)HASH ...
Nachtnebel, A.
core  

Understanding drugs in breast cancer through drug sensitivity screening [PDF]

, 2015
With substantial numbers of breast tumors showing or acquiring treatment resistance, it is of utmost importance to develop new agents for the treatment of the disease, to know their effectiveness against breast cancer and to understand their ...
Foekens, J.A. (John), Göhlmann, H.W.H. (Hinrich W. H.), Heine, A.A.J. (Anouk), Jager, A. (Agnes), Martens, J.W.M. (John), Ozturk, B. (Bahar), Prager-van der Smissen, W.J.C. (Wendy), Smid, M. (Marcel), Uhr, K. (Katharina)   +8 more
core   +4 more sources

IgG4 anti‐CD47: Erythrophagocytosis and potential transfusion complications

Transfusion, EarlyView.
Abstract Background IgG4 monoclonal anti‐CD47 for cancer immunotherapy resulted in anemia necessitating red cell (RBC) transfusions. Although the antibody readily binds to CD47 on RBCs, the mechanism underlying the anemia associated with IgG4 is poorly understood.
Kayluz Frias Boligan, Melika Loriamini, Mairead B. Holton, Gurleen Sandhu, Beth Binnington, Randall Velliquette, Connie M. Westhoff, Donald R. Branch   +7 more
wiley   +1 more source

Safety and efficacy of azacitidine in myelodysplastic syndromes

Drug Design, Development and Therapy, 2010
Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAPurpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are ...
Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-Manero   +2 more
doaj  

A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia

Haematologica
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed AML. However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of MCL-1 is suggested to be a potential resistance mechanism.
Guru Subramanian Guru Murthy, Antoine N. Saliba, Aniko Szabo, Alexandra Harrington, Sameem Abedin, Karen Carlson, Laura Michaelis, Lyndsey Runaas, Arielle Baim, Alex Hinman, Sonia Maldonado-Schmidt, Annapoorna Venkatachalam, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Mark Litzow, Scott H. Kaufmann, Ehab Atallah   +17 more
doaj   +1 more source

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

Cancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi, Zijian Zhang, Yang Yang, Haichuan Zhu   +3 more
wiley   +1 more source

Cytomegalovirus Colitis Following Azacitidine Therapy

Canadian Journal of Infectious Diseases and Medical Microbiology, 2011
The present report describes the first recognized case of cytomegalovirus (CMV) colitis following azacitidine therapy. A 66-year-old woman with myelodysplastic syndrome developed CMV colitis, which responded to treatment with ganciclovir.
Rajal Khan, Pam Rudkin, Kuljit Grewal, Jennifer Leonard, Mowafak Hamodat, Jim Hutchinson, Peter Daley   +6 more
doaj   +1 more source

Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts [PDF]

, 2013
The transition of patients with ≥20% 30% BM blast. These controversies are even more manifest when it comes to elderly patients in whom concern for intensive chemotherapy (IC) related toxicity is the critical determinant for the therapeutic choice.
Amadori, S, Buccisano, F, Ceresoli, E, Del Principe, MI, Di Caprio, L, Ditto, C, Giannotti, F, Maurillo, L, Nasso, D, Postorino, M, Refrigeri, M, Sarlo, C, Venditti, A   +12 more
core   +2 more sources

Improvement in survival of patients with higher risk but not lower risk myelodysplastic syndromes over 20 years: A retrospective study from Nagasaki, Japan

British Journal of Haematology, EarlyView.
Takafumi Furumoto, Koji Ando, Eo Toriyama, Tomoko Hata, Hikaru Sakamoto, Masahiko Chiwata, Hideaki Kitanosono, Jun Nakashima, Takeharu Kato, Masataka Taguchi, Makiko Horai, Hidehiro Itonaga, Shinya Sato, Yasushi Sawayama, Daisuke Imanishi, Yoshitaka Imaizumi, Tatsuro Jo, Shinichiro Yoshida, Yukiyoshi Moriuchi, Yasushi Miyazaki   +19 more
wiley   +1 more source

MTOR cross-talk in cancer and potential for combination therapy [PDF]

, 2018
The mammalian Target of Rapamycin (mTOR) pathway plays an essential role in sensing and integrating a variety of exogenous cues to regulate cellular growth and metabolism, in both physiological and pathological conditions.
Bazzichetto, C., Bria, E., Ciuffreda, L., Cognetti, F., Conciatori, F., Falcone, I., Milella, M, Pilotto, S.   +7 more
core   +3 more sources